|
|
Blood, 1 April 2008, Vol. 111, No. 7, pp. 3821-3829.
Prepublished online as a Blood First Edition Paper on January 30, 2008; DOI 10.1182/blood-2007-08-109330.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Ji Wu1,
Feng Meng1,
Henry Lu2,
Ling Kong1,
William Bornmann3,
Zhenghong Peng3,
Moshe Talpaz2, and
Nicholas J. Donato2
1 Department of Experimental Therapeutics, The University of Texas, M. D. Anderson Cancer Center, Houston, TX;
2 Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and
3 Department of Experimental Diagnostic Imaging, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
Lyn kinase functions as a regulator of imatinib sensitivity in chronic myelogenous leukemia (CML) cells through an unknown mechanism. In patients who fail imatinib therapy but have no detectable BCR-ABL kinase mutation, we detected persistently activated Lyn kinase. In imatinib-resistant CML cells and patients, Lyn activation is BCR-ABL independent, it is complexed with the Gab2 and c-Cbl adapter/scaffold proteins, and it mediates persistent Gab2 and BCR-ABL tyrosine phosphorylation in the presence or absence of imatinib. Lyn silencing or inhibition is necessary to suppress Gab2 and BCR-ABL phosphorylation and to recover imatinib activity. Lyn also negatively regulates c-Cbl stability, whereas c-Cbl tyrosine phosphorylation is mediated by BCR-ABL. These results suggest that Lyn exists as a component of the BCR-ABL signaling complex and, in cells with high Lyn expression or activation, BCR-ABL kinase inhibition alone (imatinib) is not sufficient to fully disengage BCR-ABL–mediated signaling and suggests that BCR-ABL and Lyn kinase inhibition are needed to prevent or treat this form of imatinib resistance.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. W. Zhang, J. E. Cortes, H. Yao, L. Zhang, N. G. Reddy, E. Jabbour, H. M. Kantarjian, and D. Jones
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
J. Clin. Oncol.,
August 1, 2009;
27(22):
3642 - 3649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Williams, I. S. Lucet, S. P. Klinken, E. Ingley, and J. Rossjohn
Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State
J. Biol. Chem.,
January 2, 2009;
284(1):
284 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O'Hare and M. W. Deininger
Toward a Cure For Chronic Myeloid Leukemia
Clin. Cancer Res.,
December 15, 2008;
14(24):
7971 - 7974.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Konig, M. Copland, S. Chu, R. Jove, T. L. Holyoake, and R. Bhatia
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Cancer Res.,
December 1, 2008;
68(23):
9624 - 9633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-X. Mahon, S. Hayette, V. Lagarde, F. Belloc, B. Turcq, F. Nicolini, C. Belanger, P. W. Manley, C. Leroy, G. Etienne, et al.
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Cancer Res.,
December 1, 2008;
68(23):
9809 - 9816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. Deininger
Persistent LYN Signaling in Imatinib-Resistant, BCR-ABL-Independent Chronic Myelogenous Leukemia
J Natl Cancer Inst,
July 2, 2008;
100(13):
908 - 909.
[Full Text]
[PDF]
|
|
|
|
|
